Apnimed touts PhIIb data for lead sleep apnea program, preparing to advance to pivotal studies

Paul Schloesser

Associate Editor

Not six months after raising cash to take a drug for obstructive sleep apnea through Phase III trials, Cambridge’s Apnimed is setting the stage with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Apnimed touts PhIIb data for lead sleep apnea program, preparing to advance to pivotal studies

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

Ap­n­imed touts PhI­Ib da­ta for lead sleep ap­nea pro­gram, prepar­ing to ad­vance to piv­otal stud­ies

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Apnimed touts PhIIb data for lead sleep apnea program, preparing to advance to pivotal studies

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A